BioLineRx Ltd. Announces Issuance Of United States Patent Covering Use Of BL-8040 In Immunotherapy
3/14/2014 8:49:39 AM
JERUSALEM--(BUSINESS WIRE)--BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that an Issue of Notification has been received from the United States Patent and Trademark Office (USPTO) for U.S. Patent No. 8,663,651, which includes claims to protect the use of BL-8040’s composition for enhancing immune responses to an antigen, such as a tumor-associated antigen. The issued patent has a term extending to October 2029. This patent is part of BL-8040’s expanding patent portfolio, which includes 13 issued patents and 25 patent applications pending worldwide, providing a strong intellectual property estate around BL-8040.
Help employers find you! Check out all the jobs and post your resume.
comments powered by